Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
49 hedge funds and large institutions have $39.7M invested in Novelion Therapeutics Inc. Common Shares in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 8 closing their positions.
70% more call options, than puts
Call options by funds: $288K | Put options by funds: $169K
8% less funds holding
Funds holding: 53 → 49 (-4)
26% less capital invested
Capital invested by funds: $53.6M → $39.7M (-$13.9M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
57% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$883K |
| 2 |
CCM
Context Capital Management
Lajolla,
California
|
+$226K |
| 3 |
Morgan Stanley
New York
|
+$61.1K |
| 4 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$17.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$15.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.32M |
| 2 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$1.07M |
| 3 |
Goldman Sachs
New York
|
-$590K |
| 4 |
Millennium Management
New York
|
-$351K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$227K |
NVLN Hedge Fund Activity: Q3 2018 in Review
49 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q3 2018, worth a combined $39.7M — down 26% from $53.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of NVLN and 4 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 6 added.
The largest buyer was Prosight Management, adding an estimated $883K. The largest seller was Fidelity Investments, cutting an estimated $2.32M.
- 49 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q3 2018, down from 53 in Q2 2018.
- Funds reported $39.7M of Novelion Therapeutics Inc. Common Shares stock for Q3 2018, down 26% quarter-over-quarter.
- 4 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q3 2018 and 8 closed out, a net change of -4 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q3 2018 was Prosight Management, an estimated $883K added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q3 2018 was Fidelity Investments, an estimated $2.32M sold.
Based on aggregated 13F filings for Q3 2018.